Emtricitabine-induced pure red cell aplasia

2Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Introduction: Anemia is common in HIV. Parvo B19 infection is a well-recognised cause of red cell aplasia. Other causes of persistent pure red cell aplasia (PRCA) include anti-retroviral drugs such as zidovudine and lamivudine. We describe a case of PRCA that strongly implicates emtricitabine as the probable cause. Patient presentation: Patient was HIV positive and on treatment with a fixed drug combination consisting of tenofovir, emtricitabine and efavirenz for 3 months when she developed severe transfusion dependent anemia. The anemia, attributed to PRCA, was persistent and transfusion dependent for about one year. Management and outcome: Replacement of emtricitabine with abacavir resulted in a prompt, complete and lasting resolution of the anaemia, suggesting an etiologic role of emtricitabine in the PRCA. Conclusion: Emtricitibine is a rare cause of pure red cell aplasia.

Cite

CITATION STYLE

APA

Manickchund, N., du Plessis, C., John, M. A. A., Manzini, T. C., Gosnell, B. I., Lessells, R. J., & Moosa, Y. S. (2019). Emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine, 20(1). https://doi.org/10.4102/sajhivmed.v20i1.983

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free